The United States of America, as Represented by the Secretary, Department of Health and Human Services

W Marston Linehan

Lance A Liotta

David B Krizman

Paul D Smith

Michael R Emmert-Buck

Robert F Bonner

Seth R Goldstein

John I Peterson

Rodrigo F Chuaqui

Berton Zbar

Jeffry M Trent

Leonard M Neckers

John A Beutler

Jane B Neckers

Laura S Schmidt

Michael L Nickerson

Maria L Turner

Michelle Warren

Min-Jung Lee

Bradley T Scroggins

James B Mitchell

Suzanne L Topalian

Michael I Lerman

Murali Krishna Cherukuri

Farida Latif

Sunmin Lee

Jorge R Toro

Carole Sourbier

Tracey A Rouault

Robert K Bright

Cathy D Vocke

Carole Ac Sourbier

Jorge P Toro

Disclosed is a method of activating protein kinase C theta (PKC&#x3b8;) in an HIV or HTLV infected animal comprising administering to the animal an effective amount of a compound of formula (I): Formula (I), or an epimer thereof; wherein Ar and R-Rare described herein. Examples of diseases or conditions associated with PKC&#x3b8; include HIV1 infection, AIDS, HTLV infection, and adult T cell leukemia/lymphoma. 

Methods of treating patients infected with HIV and HTLV

Disclosed are methods of treating an animal for insulin resistance and associated diseases or conditions, activating the transcriptional activity of heat shock factor 1 (HSF1), or inducing the expression of heat shock protein 70 (HSP70) in an animal in need thereof, wherein the methods involve administering an effective amount of one or more compounds of formula (I) or an epimer thereof, wherein Ar, and R-Rare described herein. Examples of diseases or conditions associated with insulin resistance include diabetes, obesity, inflammation, metabolic syndrome, polycystic ovary disease, arteriosclerosis, non-alcoholic fatty liver disease, reproductive abnormality in a female, and growth abnormality. 

Methods of treating or preventing insulin resistance and associated diseases and conditions

The invention provides therapeutic methods that include administering a stable nitroxide to a subject that has, is suspected to have, or is at risk for having a condition associated with reduced VHL or elevated HIF-2&#x3b1;.

Nitroxide therapy for the treatment of von Hippel&#x2014;Lindau disease (VHL) and renal clear cell carcinoma (RCC)

The present disclosure relates to Birt-Hogg-Dub&#xe9; syndrome, nucleic acids encoding the BHD gene, and antibodies that specifically bind to the BHD protein (folliculin). In addition, the present disclosure relates to methods of diagnosing BHD disease and related conditions, such as spontaneous pneumothorax and kidney cancer, by detection of altered expression of folliculin using folliculin-specific antibodies.

Folliculin-specific antibodies and methods of detection

The present disclosure relates to Birt-Hogg-Dub&#xe9; syndrome, nucleic acids encoding the BHD gene, and methods of using the nucleic acids and proteins encoded thereby. In particular, the present disclosure relates to methods of diagnosing BHD disease and related conditions, such as spontaneous pneumothorax and kidney cancer, and methods of treating BHD skin lesions.

Identification of a novel BHD gene

The present invention relates to immortalized, malignant, human, adult prostate epithelial cell lines or cell lines derived therefrom useful in the diagnosis and treatment of prostate cancer. More particularly, the present invention relates to cloned, immortalized, malignant, human, adult prostate epithelial cell lines and uses of these cell lines for the diagnosis and treatment of cancer. Furthermore, the present invention provides for the characterization of said cell lines through the analysis of specific chromosomal deletions.

Immortal human prostate epithelial cell lines and clones and their applications in the research and therapy of prostate cancer

A method of microdissection which involves forming an image field of cells of the tissue sample utilizing a microscope, identifying at least one zone of cells of interest from the image field of cells which at least one zone of cells of interest includes different types of cells than adjacent zones of cells, and extracting the at least one zone of cells of interest from the tissue sample. The extraction is achieved by contacting the tissue sample with a transfer surface that can be selectively activated so that regions thereof adhere to the zone of cells of interest to be extracted. The transfer surface includes a selectively activatable adhesive layer which provides, for example, chemical or electrostatic adherence to the selected regions of the tissue sample. After the transfer surface is activated, the transfer surface and tissue sample are separated. During separation, the zone of cells of interest remains adhered to the transfer surface and is thus separated from the tissue sample, the zone of cells of interest may then be molecularly analyzed.

Isolation of cellular material under microscopic visualization

The Von Hippel-Lindau (VHL) disease gene and its corresponding cDNA are disclosed. Methods for detecting carriers of the VHL disease gene using probes derived from the VHL disease gene sequence are described. Pharmaceutical compositions and methods of treating diseases related to the VHL gene are also disclosed.

Partial intron sequence of von hippel-lindau (VHL) disease gene and its use in diagnosis of disease

Growing community of inventors

North Bethesda, MD, United States of America

W Marston Linehan